Here are five things to know.
1. Synergy’s proprietary GI platform is based on uroguanylin, a naturally occurring human GI peptide that supports normal bowel function.
2. The company’s proprietary platform includes Trulance, a once-daily tablet approved for adults with chronic idiopathic constipation and IBS with constipation.
3. Trulance (plecanatide) is structurally identical to uroguanylin with the exception of one amino acid. Trulance is contraindicated in patients less than six years old.
4. Synergy is currently developing dolcanatide for ulcerative colitis.
5. Synergy became a public company in July 2008 and is currently listed on NASDAQ.
More articles on gastroenterology:
GI leader to know: Dr. Walter Hassig of Digestive Health Specialists
Olympus implementing InterSystems HealthShare to facilitate image sharing — 3 insights
5 things to know about EndoGastric Solutions
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
